MATINAS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 116.50 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was 173.58K shares, a 97.66% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 40.00K shares, a 95.21% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 116.50K shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 278.58K shares, a 96.73% decline from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 8.51M shares, a 22.48% decline from fiscal 2021.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 10.98M shares, a 68.84% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-31 | 116.50K shares 10-K · filed 2026-03-31 | ||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 116.50K shares 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 116.50K shares 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | 173.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | 213.58K shares derived: sum of 2 quarters · filed 2025-04-15 | 258.58K shares derived: sum of 3 quarters · filed 2025-04-15 | 278.58K shares 10-K · filed 2025-04-15 | 13.93M shares 10-K · filed 2024-03-27 |
| 2023-09-30 | 40.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 85.00K shares derived: sum of 2 quarters · filed 2023-11-08 | 105.00K shares 10-Q · filed 2023-11-08 | 7.52M shares derived: sum of 4 quarters · filed 2024-03-27 | |
| 2023-06-30 | 45.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 65.00K shares 10-Q · filed 2023-08-09 | 7.48M shares derived: sum of 3 quarters · filed 2024-03-27 | 8.31M shares derived: sum of 4 quarters · filed 2024-03-27 | |
| 2023-03-31 | 20.00K shares 10-Q · filed 2023-05-10 | 7.43M shares derived: sum of 2 quarters · filed 2024-03-27 | 8.27M shares derived: sum of 3 quarters · filed 2024-03-27 | 8.30M shares derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-12-31 | 7.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | 8.25M shares derived: sum of 2 quarters · filed 2024-03-27 | 8.28M shares derived: sum of 3 quarters · filed 2024-03-27 | 8.51M shares 10-K · filed 2024-03-27 | |
| 2022-09-30 | 835.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 870.00K shares derived: sum of 2 quarters · filed 2022-11-02 | 1.09M shares 10-Q · filed 2022-11-02 | ||
| 2022-06-30 | 35.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 260.00K shares 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 225.00K shares 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | 10.98M shares 10-K · filed 2023-03-15 | ||||
| 2020-12-31 | 963.00K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | 1.25M shares derived: sum of 2 quarters · filed 2022-03-11 | 3.01M shares derived: sum of 3 quarters · filed 2022-03-11 | 6.50M shares 10-K/A · filed 2022-03-11 | |
| 2020-09-30 | 288.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | 2.04M shares derived: sum of 2 quarters · filed 2020-11-06 | 5.54M shares 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | 1.75M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 5.25M shares 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 3.50M shares 10-Q · filed 2020-05-11 | ||||
| 2015-09-30 | 368.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | 468.89K shares derived: sum of 2 quarters · filed 2015-11-10 | 2.00M shares 10-Q · filed 2015-11-10 | 2.03M shares derived: sum of 4 quarters · filed 2015-11-10 | |
| 2015-06-30 | 100.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | 1.63M shares 10-Q · filed 2015-08-13 | 1.66M shares derived: sum of 3 quarters · filed 2015-08-13 | ||
| 2015-03-31 | 1.53M shares 10-Q · filed 2015-05-15 | 1.56M shares derived: sum of 2 quarters · filed 2015-05-15 | |||
| 2014-12-31 | 33.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | 2.41M shares 10-K · filed 2015-03-31 | |||
| 2014-09-30 | 2.38M shares 10-Q · filed 2014-11-14 | ||||
| 2013-12-31 | 3.16M shares 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |